Geron Corporation

Other

Memorial Sloan Kettering Cancer Center

Telomerase Activation Sciences, Inc.

Telomerase Activation Science, Inc.

Allison C Chin

Tsutomu Akama

Calvin B Harley

David M Miller-Martini

Nancy Yuk-yu Ip

Yung-hou Wong

Richard L Tolman

Ryan Holcomb

Hiroyuki Yamaguchi

Yutaka Kanda

Yoshinori Yamashita

Akira Asai

Mark Quang Nguyen

Nancy Yuk-Yu Ip

Mieczyslaw A Piatyszek

Malcolm As Moore

Upinder Singh

Kaori Endo

Yung-Hou Wong

Calvin B Halrley

Yung-Hou Phd Associate Professor Dept Of Biolochemistry Wong

Malcolm A S Moore

Methods and cosmetic compositions for conditioning the skin, utilizing as active ingredients selected compounds structurally related to astragenols, cycloastragenols, and/or protopanaxatriols, are provided. Such compounds include those of formulas (I), (II) and (III) described herein.

Compositions and methods for skin conditioning

The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin ailments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells.

Compositions and methods for increasing telomerase activity

A method and kit for inhibiting the proliferation of cancer cells are disclosed, based on a combination of a proteasome inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the proteasome inhibitor alone or the telomerase inhibitor alone. Preferably, efficacy is supraadditive or synergistic in nature relative to the combined effects of the individual agents, with minimal exacerbation of side effects.

Cancer treatment by combined inhibition of proteasome and telomerase activities

The present invention relates to methods for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The method and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin aliments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells.

Thiazolidinedione compounds, compositions, and methods of inhibiting telomerase activity in vitro and treatment of telomerase mediated conditions or diseases ex vivo and in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of conditions or diseases mediated by telomerase activity, such as in the treatment of cancer. Also disclosed are novel methods for assaying or screening for inhibitors of telomerase activity.

Telomerase inhibitors and methods of their use

5-(3-Isatinylidinyl)thiazolidineones and 3-(thiazolidinon-5-yl)indoles compounds, compositions, and methods of inhibiting telomerase activity in vitro and treatment of telomerase mediated conditions or diseases ex vivo and in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of conditions or diseases mediated by telomerase activity, such as in the treatment of cancer. Also disclosed are novel methods for assaying or screening for inhibitors of telomerase activity.

Substituted indole compounds and methods of their use

Growing community of inventors

Stanford, CA, United States of America

Allison C Chin